|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.91 USD | +1.53% |
|
+3.35% | -6.53% |
| 08/07 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise | MT |
| 08/07 | Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration | MT |
| Market Cap | 257.9Cr 224.14Cr 209.26Cr 192.1Cr 362.22Cr 25TCr 368.54Cr 2.47TCr 966.38Cr 12TCr 968.72Cr 947.26Cr 40TCr | P/E 2026 * |
-5.96x | P/E 2027 * | -5.71x |
|---|---|---|---|---|---|
| Enterprise Value | 172.44Cr 149.87Cr 139.92Cr 128.45Cr 242.2Cr 16TCr 246.42Cr 1.65TCr 646.17Cr 8.2TCr 647.74Cr 633.39Cr 27TCr | EV / Sales 2026 * |
21.9x | EV / Sales 2027 * | 14.6x |
| Free-Float |
98.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Beam Therapeutics Inc.
| 1 day | +1.53% | ||
| 1 week | +3.35% | ||
| Current month | +1.53% | ||
| 1 month | -25.52% | ||
| 3 months | -15.60% | ||
| 6 months | -7.10% | ||
| Current year | -6.53% |
| 1 week | 24.67 |  | 27.02 |
| 1 month | 24.67 | | 38.26 |
| Current year | 21.63 | | 38.26 |
| 1 year | 15.6 | | 38.26 |
| 3 years | 13.52 | | 49.5 |
| 5 years | 13.52 | | 116.91 |
| 10 years | 13 | | 138.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Evans
CEO | Chief Executive Officer | 48 | 01/01/2017 |
| President | 57 | 24/01/2020 | |
Sravan Emany
DFI | Director of Finance/CFO | 48 | 19/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
John Evans
BRD | Director/Board Member | 48 | 01/01/2017 |
Mark Fishman
BRD | Director/Board Member | 75 | 01/05/2018 |
Graham Cooper
BRD | Director/Board Member | 56 | 10/10/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/07/26 | Sell | Chief Technology Officer | -16,667 | 0.0162% | ||
| 30/06/26 | Fiscal year | Chief Executive Officer | 75,000 | 0.0729% | ||
| 30/06/26 | Sell | Chief Technology Officer | -373 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.53% | +3.35% | +37.60% | -4.74% | 254.02Cr | |
| -0.36% | +0.14% | -2.06% | +14.33% | 4.85TCr | |
| -2.71% | -2.99% | +398.09% | +472.12% | 3.99TCr | |
| -0.71% | +9.45% | +27.90% | +7.89% | 3.87TCr | |
| -0.71% | -3.72% | +4.94% | +52.45% | 3.51TCr | |
| -2.41% | +2.59% | +11.68% | +41.16% | 2.98TCr | |
| -0.66% | -2.73% | +35.50% | +122.17% | 1.61TCr | |
| -0.19% | -3.93% | - | - | 1.61TCr | |
| -0.62% | +1.23% | +2.76% | +15.05% | 1.36TCr | |
| -3.15% | -6.14% | -4.82% | -36.90% | 1.26TCr | |
| Average | -1.00% | +0.33% | +56.84% | +75.95% | 2.53TCr | |
| Weighted average by Cap. | -1.22% | +1.18% | +76.05% | +103.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.89Cr 6.85Cr 6.4Cr 5.87Cr 11Cr 751.75Cr 11Cr 75Cr 30Cr 374.89Cr 30Cr 29Cr 1.24TCr | 9.61Cr 8.35Cr 7.8Cr 7.16Cr 13Cr 915.7Cr 14Cr 92Cr 36Cr 456.64Cr 36Cr 35Cr 1.51TCr |
| Net income | -46Cr -40Cr -37Cr -34Cr -65Cr -4.4TCr -66Cr -441.16Cr -172.78Cr -2.19TCr -173.2Cr -169.37Cr -7.23TCr | -52Cr -45Cr -42Cr -39Cr -73Cr -4.96TCr -74Cr -498.24Cr -195.14Cr -2.48TCr -195.61Cr -191.28Cr -8.16TCr |
| Net Debt | -85Cr -74Cr -69Cr -64Cr -120.02Cr -8.15TCr -122.11Cr -817.59Cr -320.21Cr -4.06TCr -320.99Cr -313.88Cr -13TCr | -117.18Cr -101.84Cr -95Cr -87Cr -164.59Cr -11TCr -167.46Cr -1.12TCr -439.1Cr -5.57TCr -440.16Cr -430.41Cr -18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | $25.91 | +1.53% | 12,94,006 |
| 31/26/31 | $25.52 | -3.66% | 10,68,341 |
| 30/26/30 | $26.49 | +1.81% | 14,54,678 |
| 29/26/29 | $26.02 | -1.03% | 15,77,794 |
| 28/26/28 | $26.29 | +4.87% | 22,98,013 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BEAM Stock
Select your edition
All financial news and data tailored to specific country editions
